Fate Therapeutics Inc (FATE)
3.91
-0.23
(-5.56%)
USD |
NASDAQ |
May 17, 16:00
3.91
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Free Cash Flow: -139.78M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
March 31, 2024 | -139.78M |
December 31, 2023 | -138.42M |
September 30, 2023 | -183.66M |
June 30, 2023 | -208.55M |
March 31, 2023 | -241.14M |
December 31, 2022 | -283.77M |
September 30, 2022 | -290.37M |
June 30, 2022 | -274.76M |
March 31, 2022 | -257.19M |
December 31, 2021 | -213.57M |
September 30, 2021 | -147.85M |
June 30, 2021 | -131.42M |
March 31, 2021 | -47.50M |
December 31, 2020 | -44.16M |
September 30, 2020 | -49.35M |
June 30, 2020 | -38.76M |
March 31, 2020 | -99.07M |
December 31, 2019 | -90.57M |
September 30, 2019 | -74.58M |
June 30, 2019 | -57.76M |
March 31, 2019 | -47.46M |
Date | Value |
---|---|
December 31, 2018 | -40.95M |
September 30, 2018 | -40.33M |
June 30, 2018 | -46.18M |
March 31, 2018 | -43.67M |
December 31, 2017 | -38.54M |
September 30, 2017 | -34.62M |
June 30, 2017 | -32.03M |
March 31, 2017 | -30.46M |
December 31, 2016 | -30.28M |
September 30, 2016 | -29.84M |
June 30, 2016 | -30.07M |
March 31, 2016 | -20.50M |
December 31, 2015 | -19.90M |
September 30, 2015 | -19.17M |
June 30, 2015 | -17.09M |
March 31, 2015 | -24.48M |
December 31, 2014 | -23.30M |
September 30, 2014 | -21.60M |
June 30, 2014 | -19.39M |
March 31, 2014 | -17.33M |
December 31, 2013 | -15.62M |
Free Cash Flow Range, Past 5 Years
-290.37M
Minimum
Sep 2022
-38.76M
Maximum
Jun 2020
-150.61M
Average
-139.10M
Median
Free Cash Flow Benchmarks
Amicus Therapeutics Inc | -88.03M |
Sarepta Therapeutics Inc | -653.88M |
ADMA Biologics Inc | 15.91M |
Ocular Therapeutix Inc | -87.11M |
Viking Therapeutics Inc | -54.87M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | -33.35M |
Cash from Investing (Quarterly) | 17.31M |
Cash from Financing (Quarterly) | 95.49M |
Free Cash Flow Per Share (Quarterly) | -0.3307 |
Free Cash Flow to Equity (Quarterly) | -33.44M |
Free Cash Flow Yield | -36.05% |